| Objective Determining the expression profiles of P16 in esophageal carcinoma tissue of high incidence area, and analyzing the relationship of the expression with clinic-pathological characteristics and prognosis of patients with esophageal carcinoma.Methods Retrospective analysis 55 patients having undergone radical esophageal carcinoma surgery in the 82 th Hospital of PLA from Jan. 2011-Jan. 2013, and employing the immuneohistochemistry to examine the P16 expression in the primary tumor. At last, we could analyze the relation of P16 expression in the primary tumor with clinicopathological characteristics and prognosis of patients. Results In 55 samples, in term of the expression of P16, there 41.8%(23/55) person were positive expression, the person of P16 negative expression were 58.2%(32/55), and the positive expression of P16 is mainly located in nucleus of the tumor-cell. Besides, the relationship of the positive expression with the year(P=0.03)、general type of tumor tissue(P=0.044)、metastatic lymph nodes(P=0.049) had positive correlation, which were negative correlation with sexuality(P=0.781)、the location of tumor( P=1.00)、the length of tumor(P=0.686)、degree of differentiation(P=1.00)、depth of infiltration(P=0.418)and the hobby of smoking and drinking. Which reveal the expression of P16 is correlation with prognosis of esophageal carcinoma. In addition, Kaplan-Meier survival analysis showed the 3-year OS of P16 positive expression was 43.5%(10/23),MST was 34 months, P16 negative expression was 25%(8/32), MST was 26 months(χ2=4.208 P=0.040). The 3-year DFS of patients with P16 positive expression was30.4%(7/23), MDFS was 28 months, however, the DFS of negative expression was18.8%(6/32), MDFS was 18 months(χ2=4.096 P=0.043). Besides, the 3-year OS was 55.6%(15/27) for the year<60, MST was 36 months, the OS was 10.7%(3/28) forthe year ≥60,MST was 22 months(P<0.01). T1-T2 was 59.3%(16/27) for the 3-year OS, MST was 36 months, T3-T4 was 7.1%(2/28), MST was 26 months(P<0.01). The patients of no lymphatic metastasis were 50.0%(17/34) for 3-year OS, MST was 35 months, the OS of 9.5%(2/21) was lymphatic metastasis, MST 20 months(P<0.01).Although, the 3-year OS of female had no above significance with male, the 3-year OS of female was much higher than male(45.0% VS 25.7% P=0.308). The 3-year OS of the tumor located in middle was also no significance comparing with the tumor located in down(33.3% VS 28.6% P=0.672). Besides, the 3-year OS and DFS of the tumor length<5cm were much higher than ≥5cm, but had no significance(34.7% VS 16.7% 29 months VS 16 months P=0.256). Among general type, the 3-year OS of lump、medulla、ulcer and stegnosis were 45.5%、36.4%、21.7% and 0%, the 3-year DFS were 33months、33 months、28months、22 months, but they had no significance among these types(P=0.400), which demonstrated the 3-year OS of lump and medulla were much higher than ulcer and stegnosis. The 3year OS was 34.4% in well differentiation in the tumor, MST was 29 months, the low differentiation in the tumor was 0%, MST was 24 months, which had no significance(P=0.294). Although, the 3-year OS of receiving adjuvant therapy was much higher than un-receiving adjuvant therapy, they were no significance(34.1% VS 28.6% P=0.968), which also revealed the adjuvant therapy could prolong the OS of patients. At last, the 3-year OS having hobby of smoking and drinking also had no significance(P=0.502). Besides, for DFS, there was 44.4%(12/27)for the below 60, MDFS was 30 months, greater than or equal to 60 was 7.1%(2/28),MDFS was 17 months(P<0.01). T1-T2 was 44.4%(12/27) for the 3-year DFS, MDFS was 30 months, 7.1%(2/28) was T3-T4, MDFS was 18 months(P<0.01). The 38.2%(13/34) was patients of no lymphatic metastasis for3-year DFS, MDFS was 26 months,9.5%(2/21) was lymphatic metastasis, MDFS was 15 months(P<0.01). But, the relationship between DFS with other clinico- pathological characteristics, for example,sexuality、 length of the tumor、type of the tumor、the location and so on, both of them had no correlation(P>0.05). At last, Cox regression analysis revealed the time of life in patients(P=0.007), depth of infiltration(P=0.019) and metastatic lymph nodes(P=0.001) could act as an independently prognosis factor for OS of patients. In addition,we also found the time of life in patients(P=0.008), depth of infiltration(P=0.004) and metastatic lymph nodes(P=0.026) were also affect independently DFS of patients. But in this experimentation, we discovered P16 couldn’t forecast independently the OS(P=0.370) and DFS(P>0.05) of patients, because of it easily was affected by other clinicopathological characteristics which resulted in stabilization of the P16 reduce.Conclusions In my experimentation, the expression of P16 was obvious decline in esophageal carcinoma, and the deletion of P16 in esophageal carcinoma was a poor prognosis factor, but it couldn’t act as an independently affect factor for prognosis of esophageal carcinoma because of its instability. |
PDF Full Text Request